Nimotuzumab

Drug Profile

Nimotuzumab

Alternative Names: Anti-EGFR mAb hR3; BIOMAb EGFR; CIMAher; Cimaher; DE-766; h-R3; KI-0501; KI-0502; OSAG101; Taixinsheng; TheraCIM; TheraCIM hR3; Theraloc; VECTHIX

Latest Information Update: 22 Nov 2016

Price : $50

At a glance

  • Originator Center of Molecular Immunology; CIMYM
  • Developer Biocon Biopharmaceuticals; Biotech Pharmaceutical; Center of Molecular Immunology; CIMYM; Daiichi Sankyo Inc; Eurofarma; Gilead Sciences; Innogene Kalbiotech; InnoMab; Kuhnil Pharmaceutical Company; Laboratorios Pisa; Oncoscience
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Glioma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Anaplastic astrocytoma; Brain cancer; Glioblastoma; Glioma; Head and neck cancer; Nasopharyngeal cancer; Oesophageal cancer
  • Phase III Gastric cancer; Non-small cell lung cancer; Pancreatic cancer
  • Phase II/III Breast cancer
  • Phase II Cervical cancer; Colorectal cancer
  • Clinical Phase Unknown Polycystic kidney disease
  • No development reported Prostate cancer
  • Discontinued Brain metastases; Squamous cell cancer

Most Recent Events

  • 14 Oct 2016 The Center of Molecular Immunology plans a phase-I/II clinical trial in Breast cancer (Combination therapy, First-line therapy, Metastatic disease) in Cuba (SC) (RPCEC00000218)
  • 31 May 2016 Daiichi Sankyo completes a phase II trial for Non-small cell lung cancer (First-line therapy; Combination therapy, Late-stage disease) in Japan (JapicCTI090825)
  • 29 Apr 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top